A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy And Safety Of Rivipansel (Gmi-1070) In The Treatment Of Vaso-occlusive Crisis In Hospitalized Subjects With Sickle Cell Disease

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy And Safety Of Rivipansel (Gmi-1070) In The Treatment Of Vaso-occlusive Crisis In Hospitalized Subjects With Sickle Cell Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2017

At a glance

  • Drugs Rivipansel (Primary)
  • Indications Sickle cell anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms RESET
  • Sponsors Pfizer
  • Most Recent Events

    • 13 Nov 2017 Planned End Date changed from 17 Jul 2018 to 10 Jul 2018.
    • 13 Nov 2017 Planned primary completion date changed from 17 Jul 2018 to 10 Jul 2018.
    • 25 Oct 2017 Planned End Date changed from 10 Jul 2018 to 17 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top